GSK Q2 2026 Pipeline Acceleration Fuels Earnings Growth

GSK Q2 2026 Pipeline Acceleration is driving clear gains for the company and the wider pharmaceutical sector by fueling growth in specialty medicines and vaccines, while also supporting more than 20 phase III trial starts this year. This strategy expands late-stage assets while cutting costs to fund R&D portfolio expansion.

Core operating profit rose 7 percent, while core EPS grew 9 percent. Specialty medicines sales reached £3.8 billion, marking a 14 percent increase, and vaccines sales hit £2.3 billion, up 8 percent. Oncology sales advanced 17 percent, with respiratory immunology sales rising 19 percent. Arexvy sales more than doubled, results that stem from a strong product mix and solid demand in the US and Europe, even as general medicines sales fell 9 percent.

Pipeline Developments

GSK advanced its late-stage pipeline investment through key moves, including the Nuvalent acquisition that added assets such as Jideytro and neladalkib, both targeting non-small cell lung cancer. Positive phase III data supported Ris-Rez in lung cancer and backed Jemperli in rectal cancer, while Arexvy gained approval in Japan, Momelotinib received orphan drug status, and Camlipixant development ended.

Ad

Strategic Initiatives

GSK launched a three-year Accelerate Growth programme targeting £1.9 billion in annual savings by 2029, with most savings supporting R&D reinvestment. The company will open a new R&D centre in Cambridge, UK, as it plans to accelerate seven assets across 18 indications spanning oncology, respiratory disease, hepatology, and vaccines. Data comes from quarterly tables and clinical updates, with The full Q2 2026 results announcement detailing all figures and milestones.

This pipeline acceleration forms a central part of the GSK Q2 2026 Pipeline Acceleration and may improve patient access in oncology and respiratory care, offering a model for balancing innovation with stable margins that could help firms handle patent expiries through 2030.

Frequently Asked Questions

How does GSK fund its R&D acceleration?

GSK uses a three-year cost savings programme. Most funds go to late-stage trials and new launches.

What drove core profit growth in Q2 2026?

Higher specialty and vaccine sales offset extra R&D costs. A favorable regional mix helped.

Where can readers access full earnings data?

The Q2 2026 results announcement contains all tables and pipeline updates.